(34) reported a phase I/II data investigating the role of 4-1BB CD19 CAR-T cells in adult ALL, demonstrating prolonged EFS in patients who received HSCT after CAR-T therapy. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.